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Abstract
Background: Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world
and constitutes the leading cause of cancer-related death among men, and second among women
in Taiwan. Liver cirrhosis and HCC are relatively prevalent, and 80% to 85% of the patients with
these conditions have positive results for hepatitis B surface antigen in Taiwan. Only 5% of the
general population is seronegative for all hepatititis B virus (HBV) markers. This is the first study
to determine the role of ezrin upon HBV HCC cell and patients with HBV HCC undergoing
hepatectomy
Methods: Immunohistochemical study with ezrin in 104 human HBV-HCC cases were carried out
to investigate its association with the clinicopathological features and the outcomes of 104 HBV-
HCC patients undergoing hepatetomy. In addition, DNA constructs including the wild type ezrin
(wt-ezrin) and mutant ezrin Tyr353 (Y353) were transfected into Hep3B cell to study its role in
tumor invasion and differentiation.
Results: HBV HCC patients with ezrin over-expression independently have smaller tumor size,
cirrhotic liver background, poor tumor differentiation, and more vascular invasion. Ezrin
expression status has no impact on survival for HBV-HCC patients undergoing hepatectomy. The
in vitro assay showed that wt-ezrin Hep3B cells have a significant higher level of AFP secretion and
higher invasion ability as compared with the control and Y353- ezrin Hep3B cells.
Conclusion: Ezrin over-expression contributed to de-differentiation and invasion of HBV-HCC
cell. HBV-HCC patients with ezrin over-expression were independently associated with tumor
with smaller size, cirrhotic liver background, poor differentiation, and vascular invasion.
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Background
Hepatocellular carcinoma (HCC) is a common disease in
Taiwan, with an age-adjusted incidence of 28.7 per
100000 of the population per annum. It continues to be
the leading cause of cancer-related death among men and
the second among women [1]. In Taiwan, liver cirrhosis
and HCC are relatively prevalent, and 80% to 85% of the
patients with these conditions have positive results for
hepatitis B surface antigen (HBsAg) [2-4]. Only 5% to 6%
of the general population is seronegative for all HBV
markers [2-4]. Our previous study revealed the positive
rates of HBsAg and hepatitis C virus antibody were 61.9%
and 35.3%, respectively, in patients with HCC undergoing
hepatic resection [5].
The recent identification of ezrin, the product of the Villin
2 gene, as a crucial molecule in the dissemination of two
pediatric tumors adds new protein to the list of metasta-
sis-associated molecules [6,7]. Ezrin is a member of the
ERM (ezrin-radixin-moesin) cytoskeleton-associated pro-
tein family [8], sharing a homology with the amino-termi-
nal membrane-binding domain of erythrocyte band 4.1
and possessing membrane-cytoskeleton linking functions
[9]. Ezrin plays a positive role in maintaining cell shape
and polarity and participates in cell migration, signaling,
growth regulation, and differentiation [10]. Ezrin can
interact with several membrane proteins, including CD44
[11], CD43 [11], intercellular adhesion molecule-1 and
intercellular adhesion molecule-2, and phosphatidyli-
nositol [4,5]-bisphosphate [12]. In addition, ezrin can sig-
nal cell survival through the phosphatidylinositol 3-
kinase/Akt pathway [13]. Ezrin is also actively involved in
regulating the growth and metastatic capacity of cancer.
Over-expression of ezrin has been detected in several
human epithelial tumors, including prostate cancer
[14,15], brain hemangioblastoma [16], uterine endome-
trioid adenocarcinoma [17], osteosarcoma [18], and
uveal malignant melanoma [19].
However, the role of ezrin on HBV-HCC is unknown. The
aim of this study was to help to determine the role of ezrin
upon patients with HBV HCC undergoing hepatectomy in
terms of demographics, laboratory data, operative find-
ings, pathological features, and survival. In addition, in
vitro study using DNA constructs including the wild type
ezrin (wt-ezrin) and Tyr353 mutant ezrin (Y353-ezrin)
were transfected into Hep3B cell to study its role in tumor
invasion and differentiation.
Methods
Clinicopathological features of HBV HCC patients
From 1985 to 2001, 104 HBV HCC patients undergoing
hepatectomy at department of surgery, Chang Gung
Memorial Hospital, Taipei, Taiwan were investigated. Lab-
oratory tests were performed on the day before surgery.
Child grading was used to classify the severity of cirrhosis
of HBV HCC patients. The study was approved by the local
institutional review board (IRB) of Chang Gung Memorial
Hospital in the genetic transfection and clinical study and all
patients gave informed consent before taking part in the study
for immunostaining (No: 94-955B). Histopathological find-
ings of HCC were divided into four grades according to
Edmondson and Stainer's system [20]. Grades I and II
were conditioned as low-grade HCC, and grades III and IV
as high-grade.
Follow-up study
Follow-up evaluation involved clinical physical examina-
tions and blood chemistry tests at each visit. The remnant
liver was examined using abdominal ultrasonography
(US) every three months, and the serum α-fetoprotein
(AFP) was measured by radioimmunoassay at least every
3 months. When US detected a new lesion, or elevated
AFP was noted, an abdominal CT, MRI, or liver scan was
performed for confirmation. Chest x-ray examination was
performed every 6 months for pulmonary metastasis eval-
uation. If a patient complained of bone pain, a bone scan
was performed for the detection of metastasis. If any of
the above procedures indicated recurrence, the patient
was readmitted for further investigation, including an
angiographic evaluation or MRI.
Cell culture
Hep 3B, a stable hepatitis-B related human HCC cell line
containing an integrated hepatitis B virus genome, was
routinely maintained in DMEM medium. This medium
contains 5 mg/mL phenol red and supplemented with
10% fetal bovine serum (FBS), 2 mM L-glutamine and 50
mg/mL each of penicillin and streptomycin (all purchased
from Life Technologies Ltd, Paisley, UK).
Mutagenesis and cell transfection
An expression construct with VSV-G-tagged human wild
type ezrin (wt-ezrin) and Y353 mutant ezrin were a kindly
provided by Professor Monique Arpin [13]. Hep 3B cell
was seeded at a density of 1.5 × 106/60 mm dish in 2 ml
of DMEM medium one day before transfection. Transfec-
tion of ezrin expression constructs was performed using
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer instructions. Neomycin
was added into the culture medium for selecting posi-
tively transfected clones.
Western Blotting
Hep 3B cell was cultivated and treated as described above.
The cells were harvested using RIPA buffer with protease
inhibitor. Protein concentration was determined with
BCA Protein Assay Reagent (Pierce, USA). Equal amounts
of protein were denatured with loading buffer, separated
on a 12% SDS-PAGE gel (Invitrogen Life Technologies,BMC Cancer 2009, 9:233 http://www.biomedcentral.com/1471-2407/9/233
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UK) and blotted onto a PVDF membrane (Amersham,
Life Science, UK). Membranes were then blocked in a Tris-
buffered saline solution with 5% BSA or nonfat dry milk
and probed with primary antibody. The membranes were
further probed with HRP-conjugated goat anti-mouse/
anti-rabbit to visualize band. Mouse monoclonal anti-
human ezrin antibody was obtained from company (Ab-
1; Neomarker, Lab Vision, CA, USA) and mouse anti-VSV-
G antibody was obtained from Roche.
Matrigel invasive assay
Matrigel was purchased from Becton Dickinson (San Jose,
CA, USA) and stored at -20°C. After thawing at 4°C over-
night, matrigel was diluted in serum free-cold DMEM
medium and 50 ul were evenly inoculated onto upper
chamber of 6.5 mm transwell membrane and allowed to
form a gel at 37°C incubator. The Matrigel invasive assay
was carried out according to the manufacturer's instruc-
tions. A 0.2 mL of aliquot of cell suspension containing
3.3 × 105 cells was seeded on the upper chamber of
Matrigel coated transwell filter (8 um pore). The serum-
containing medium was added to the lower chamber and
incubated for 48 hrs at 37°C in a humidified atmosphere
of 5% CO2. Non-invading cells that remained on the
upper surface of the filter were removed with cotton wool;
the cells that appeared on the lower surface of the filter
were fixed in 4% paraformaldehyde, stained with hema-
toxylin and counted under a microscope. Each assay was
carried out in triplicate in three different occasions.
Differentiation assay
Detection of alpha-fetoprotein by radioimmunoassay and
albumin by biochemical test: 5 × 106  cells in 10 ml
medium were plated in 100 mm culture plate. Incubate
cells at 37°C in a CO2 incubator for 40 hours. The super-
natant was harvested for test and cell number was counted
for adjustment.
Immunohistochemistry
From the archives of Chang Gung Memorial Hospital
(from 1985 to 2001), each case of HCC was selected based
on the availability of sufficient quantities of tumor cells.
H&E-stained slides from each case were reviewed. 4 μm
section of 104 patients with HBV related HCCs from for-
malin-fixed, paraffin-embedded tissue were stained for
ezrin. The primary antibody ezrin was diluted to 1:1500
and added to the slides to be incubated overnight at 4°C.
The slides were then washed three times for 5 minutes in
TBST before visualization with the "DAKO LSAB2 System,
Peroxidase" DAKO A/S, No K0675). Control slides were
incubated with secondary antibody only. After washing
three times for 5 minutes each in TBST, the slides were
mounted and analyzed under microscope by authors
blindly.
Statistical analysis
All data are presented as percentage of patients or mean
with standard deviation. Numerical data were compared
by independent two-sample t tests. Nominal data were
compared by Pearson chi-square test, Fisher exact test or
multiple forward stepwise logistic regression test when
appropriate. Survival was calculated and plots constructed
according to the Kaplan-Meier method. Furthermore, the
log-rank test was performed for a statistical univariate
analysis of prognostic variables. All statistical analyses
were performed using the SPSS computer software pack-
age (Version 10.0, Chicago, IL, USA). A value of P ≤ 0.05
was considered significant.
Results
Clinicopathological features of 104 HBV HCC patients 
after hepatectomy regarding ezrin staining status
Table 1 summarized the clinicopathological features of
104 HBV HCC patients, including 86 men and 18 women
with a median age of 53.4 years. All the 104 patients were
positive for hepatitis B surface antigen. Among them, 67
out of 104 (64.4%) patients had underlying cirrhosis and
all the 67 patients had Child A grading. 64 out of 104
patients had high grade HCC (grade III and IV) (61.5%),
Table 1: Clinicopathological features of 104 patients with 
hepatitis-B HCC undergoing hepatectomy
Demographic data
Male: Female 86:18
Age (years) (median; range) 53.4; 23–79
AFP (ng/ml) (median; range) 143; 3–10001
HBsAg positive, (%) 104 (100)
Tumor size (cm) (median; range) 5.0; 1.5–20.5




Extent of hepatic resection
Extended right lobectomy 10 (9.6%)
Right lobectomy 17 (16.3%)
Extended left lobectomy 5 (4.8%)
Left lobectomy 13 (12.5%)
Partial hepatectomy 59 (56.7%)
Pathological features
Tumor differentiation (I, II, III, and IV) 3,37,54,10
Capsular invasion 66/104 (63.5%)
Vascular invasion 25/104 (24.0%)
Satellite lesions 27/104 (26.0%)
Recurrence 68/104 (65.4%)
HBsAg: hepatitis B surface antigenBMC Cancer 2009, 9:233 http://www.biomedcentral.com/1471-2407/9/233
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66 capsular invasion (63.5%), 25 vascular invasion
(24.0%), 27 satellite lesions (26.0%), and 68 recurrence
after hepatectomy (65.3%). Regarding staining status of
ezrin, the HBV-HCC patients with positive ezrin immuno-
reactivity had smaller tumor size, higher frequency of cir-
rhosis, tumor de-differentiation, satellite lesions, and
vascular invasion. Multivariate forward logistic regression
analysis showed that small tumor size, cirrhotic liver,
poor differentiation, and vascular invasion are the four
independent factors associated with HBV HCC patients
with positive ezrin immunoreactivity (Table 2 and 3).
Positive fluorescent and western blotting of ezrin-vsvg 
expressed in Hep 3B cells
Figure 1 upper row illustrated positive fluorescent staining
of VSVG in the wt-ezrin and Y-353 Hep 3B cells, indicat-
ing successful transfection of ezrin into Hep 3B cells. Fig-
ure 1 lower row depicted western blotting of VSVG
expression in the wt-ezrin and Y353-ezrin Hep 3B cells,
meaning successful functional expression of ezrin con-
struct in the transfected Hep 3B cells.
Ezrin Is Important for the Matrigel Invasion of Hep 3B Cell 
Lines
We studied the possibility of ezrin being involved in the
regulation of the invasive properties of Hep3B. Figure 2
illustrates that ezrin transfected Hep 3B cells have signifi-
cant higher invasiveness than Hep 3B cells. However,
inhibition of ezrin function as shown in theY353-ezrin
clones has significantly reduced the invasion of Hep 3B.
Determination of AFP and ALB concentration in the 
extracellular medium
AFP and ALB in the extracellular medium is produced and
released into extracellular fluids by cells. The appearance
of AFP and ALB in the medium further confirms tumor
cell de-differentiation and differentiation, respectively. In
our experiments, wt-ezrin Hep 3B cell secreted significant
higher AFP level when compared with Hep 3B cell, indi-
cating ezrin is associated with de-differentiation of Hep
3B cells. But Y353-ezrin clones secreted significant lower
AFP level when compared with wt-ezrin clones and the
control Hep 3B cells (Figure 3). Albumin level is too low
to be detected.
Immunohistochemistry
Figure 4A illustrated that ezrin is not stained in the normal
hepatocyte but positive in the lymphocyte and cholangi-
ocyte (cholangiocyte and lymphocyte can be used as inter-
nal positive control). Among the 104 HBV HCC patients
undergoing hepatectomy, 27 (29.6%) had variable posi-
tive ezrin immunoreactivity in the cytoplasm of the tumor
cell (Figure 4B, C, and 4D).
Survival analysis of HBV-HCC patients undergoing 
hepatectomy in terms of ezrin staining status
All of the 104 HBV-HCC patients undergoing hepatec-
tomy were closely followed at regular intervals until death
or until the time of this writing. The median follow-up
period of the 104 HBV-HCC patients undergoing hepate-
ctomy is 36.4 months (range: 1.05–134.0 months). Simi-
lar disease-free survival (DFS) and overall survival (OS)
rate were observed between the ezrin positive and ezrin
negative HBV-HCC patients after hepatectomy. The 1-, 3-
, and 5-year DFS rates between ezrin positive and ezrin
negative HBV-HCC patients after hepatectomy are similar.
Furthermore, the 1-, 3-, and 5-year OS rate between the
ezrin positive and ezrin negative HBV-HCC patients after
hepatectomy are also similar.
Discussion and Conclusion
Ezrin is a key signaling molecule that regulates cell sur-
vival, adhesion, migration, and invasion, which plays a
role of linker protein with capacity to bind membrane
proteins and the actin cytoskeleton, such interaction pro-
vides an intracellular scaffold for the formation of special-
Table 2: Clinicopathological features between Ezrin (+) and Ezrin (-) hepatitis-B HCC patients
E (+) (n = 27) (%) E (-) (n = 77) (%) P
Age (years) 51.1 ± 13.3 52.6 ± 13.4 0.631
Gender (M:F) 24:3 62:15 0.323
Tumor size (cm) 5.0 ± 4.3 7.0 ± 4.7 0.049
AFP(ng/ml) 1288.1 ± 2898.0 2215.3 ± 3701.7 0.201
Cirrhosis (+) 23 (85.2) 44 (58.7) 0.013
Grading (Edmonson and Stainer) 0.044
Low-grade (I+ II) 6 (22.2) 34 (44.2)
High-grade (III+ IV) 21 (77.8) 43 (55.8)
Capsule formation (+) 16 (58.9) 50 (64.9) 0.642
Vascular invasion (+) 12 (44.4) 13 (16.9) 0.004
Satellite lesions (+) 11 (40.7) 16 (21.3) 0.050
Recurrence (+) 17 (63.0) 51 (66.2) 0.759
M: male; F: female; AFP: α-fetoproteinBMC Cancer 2009, 9:233 http://www.biomedcentral.com/1471-2407/9/233
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ized membrane domains that facilitate signal
transduction through a number of growth factor receptor
and adhesion molecules [21]. The main function of ezrin
was first known to interact with p85, the regulatory subu-
nit of PI3-kinase (PI3K), which was involved in determin-
ing survival of epithelial cells by activating the PI3K/Akt
pathway [13]. Subsequently, the regulation of adhesion,
migration and invasion were observed [21] and proved
important to tumor development and progression [21].
Although, over-expression of ezrin has been detected in
several human epithelial tumors, including brain heman-
gioblastoma [16], uterine endometrioid adenocarcinoma
[17], osteosarcoma [18], and uveal malignant melanoma
[19], this is the first study to investigate the role of ezrin
on HBV-HCC from cell level to patients with HBV-HCC
undergoing hepatectomy.
HBV-HCC patients with positive ezrin immunoreactivity
had smaller tumor size, higher frequency of cirrhosis,
tumor dedifferentiation, satellite lesions, and vascular
Table 3: Multiple forward stepwise logistic regression analysis of clinicopathological features in 104 surgical resected hepatitis-B HCC 
cases (Ezrin (+) and Ezrin (-) group)
Odds ratio 95% CI for Odds Ratio: Lower-Upper P
Size<3 cm/>3 cm 3.174 1.083–9.301 0.035
Cirrhosis/Non-cirrhosis 4.464 1.269–15.625 0.020
Edmonson-Steiner 0.027
Gr III+IV/Gr I+II 3.759 1.161–12.195
Vascular invasion (+)/(-) 4.149 1.314–12.987 0.015
Satellite lesions (+)/(-) NS
Upper row: Positive fluorescent staining of VSVG in the wild type (wt) ezrin and Y-353 Hep 3B cells, indicating successful trans- fection of ezrin into Hep 3B cells Figure 1
Upper row: Positive fluorescent staining of VSVG in the wild type (wt) ezrin and Y-353 Hep 3B cells, indicating 
successful transfection of ezrin into Hep 3B cells. Lower row: Western blotting of VSVG in the wt-ezrin and Y-353 Hep 
3B cells, meaning successful functional expression of ezrin construct in the transfected Hep 3B cells.BMC Cancer 2009, 9:233 http://www.biomedcentral.com/1471-2407/9/233
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invasion. Multivariate forward logistic regression analysis
showed that small tumor size, cirrhotic liver, poor differ-
entiation, and vascular invasion are the four independent
factors associated with HBV HCC patients with positive
ezrin immunoreactivity.
Regarding differentiation, HBV-HCC patients with posi-
tive ezrin immunoreactivity had more poor differentia-
tion. In vitro study, we demonstrated increased activity of
ezrin resulted in de-differentiation of Hep3B cell as shown
increased secretion of AFP and absence of albumin secre-
tion. Recently, the activated PI3K-Akt-mTOR pathway has
recently emerged as a novel contributor to HCC develop-
ment [22]. Furthermore, PI3K-Akt-mTOR pathway is asso-
ciated with ezrin. Sustained activation of mTOR impaired
the hepatocytic differentiation capability of these cells as
shown by impaired formation of bile canaliculi, absence
of polarity, and reduced secretion of A1-antitrypsin.
Decrease in the activity of mTOR observed on hepatocytic
differentiation of the HepaRG cell (a cell line established
from the nontumoral region of a resected HCV-associated
HCC). Increased Akt-mTOR activity contributed to dedif-
ferentiation of HepaRG cells [23]. Similar to HepaRG
cells, increased activity of ezrin may increase the activity of
PI3K-Akt-mTOR pathway resulting in de-differentiation
of Hep3B cell. Therefore, the role of ezrin in HCC differ-
entiation could probably mediate through the pathway of
PI3K-Akt-mTOR.
Regarding invasion, increased activity of ezrin contributed
to increased invasiveness of Hep3B cell as shown
increased invasion of matrigel invasion assay.
On the other hand, decreased activity of ezrin by transfec-
tion of dominant-negative mutant (Y353) dramatically
decreased the invasion ability of HCC cell line, because
Wt-ezrin Hep 3B cells had significant higher invasiveness than Hep 3B cells Figure 2
Wt-ezrin Hep 3B cells had significant higher invasiveness than Hep 3B cells. However, inhibition of ezrin function 
using Y353-ezrin mutatnt significantly reduces invasion Hep 3B cells.BMC Cancer 2009, 9:233 http://www.biomedcentral.com/1471-2407/9/233
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Y353 ezrin change the antiapoptotic signal of ezrin to
apoptosis [13]. In experimental invasion assay, demon-
strating that ezrin over-expression is sufficient to confer
metastatic capability. HBV-HCC patients with positive
ezrin immunoreactivity had more vascular invasion but
no higher rate of recurrence. This contradiction could be
explained by HBV-HCC patients with positive ezrin
immunoreactivity having smaller tumor size.
Regarding survival, ezrin expression was not an independ-
ent prognostic factor for HBV-HCC patients after hepatec-
tomy with long-term disease-free survival and overall
survival. Small tumor size, cirrhotic liver, poor differenti-
ation, and vascular invasion are the four independent fac-
tors associated with HBV HCC patients with positive ezrin
immunoreactivity.
Our previous study has demonstrated that overall survival
and disease-free survival for small sized HCC is better
than large HCC [24]. Patients with long-term disease-free
survival after hepatectomy usually had lower rate of
underlying liver cirrhosis. The effect of underlying cirrho-
sis in the non-tumorous liver on risk of recurrence after
HCC resection is, however, controversial, although cirrho-
sis was reported to be a significant risk factor for recur-
rence in the remaining liver, owing to a predisposition to
multicentric hepatocarcinogenesis [25]. In addition,
when the patients with low-grade HCC after hepatectomy
was related with the long-term disease-free survival, how-
ever, the prognostic significance of histological grading of
HCC on risk of recurrence is debatable [26]. Vascular inva-
sion is the most consistently reported risk factor for recur-
rence after HCC resection [27]. Intrahepatic portal vein
involvement is widely accepted as the mechanism for int-
rahepatic recurrence for HCC. Although our study shows
that expression of ezrin is related to tumor differentiation
status and vascular invasion ability, its expression has no
significant impact on survival for our patient group. In
addition, the expression of ezrin has an inversely relation-
ship with the tumor size. This seems to be a conflicting
outcome of our analysis, however, as we were looking at a
group of patient who received surgical treatment, the
result can not truly reflect the impact of this marker on
HCC patients. In general, one would expect that, patient
with smaller tumor size would have a better outcome if
completely resection of the tumor can be made. Taken
together, our result of ezrin expression status has no
impact on survival for HBV-HCC patients who had under-
gone hepatectomy has to be carefully interpreted. There-
fore, it would be of importance to study the expression of
Wt-ezrin Hep 3B cell secreted significant higher AFP level when compared with Hep 3B cell, indicating ezrin is associated with  de-differentiation of Hep 3B cells Figure 3
Wt-ezrin Hep 3B cell secreted significant higher AFP level when compared with Hep 3B cell, indicating ezrin is 
associated with de-differentiation of Hep 3B cells. But Y-353 Hep 3B cell secreted significant lower AFP level when 
compared with wt-ezrin Hep 3B and Hep 3B cells.BMC Cancer 2009, 9:233 http://www.biomedcentral.com/1471-2407/9/233
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ezrin including other hepatitis related HCC patients in
order to establish its role as an independent prognostic
marker for HCC.
In conclusion, over-expression of ezrin in HBV-HCC
patients was independently associated with small tumor
size, cirrhotic liver, poor differentiation, and vascular
invasion. Ezrin over-expression contributes to de-differen-
tiation and invasion of HBV-HCC cell.
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